Peregrine Asset Advisers’s Antares Pharma, Inc. ATRS Stock Holding History

Peregrine Asset Advisers’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-53,034	Closed	-$97K	–	140
2014 Q3	$97K	Hold	53,034	–	–	0.08%	113
2014 Q2	$142K	Hold	53,034	–	–	0.13%	111
2014 Q1	$186K	Hold	53,034	–	–	0.14%	110
2013 Q4	$237K	Hold	53,034	–	–	0.21%	92
2013 Q3	$215K	Buy	53,034 +11,800	+29%	+$51.5K	0.21%	129
2013 Q2	$172K	Buy	+41,234	New	+$159K	0.18%	126

Other funds holding ATRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

WHI

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Peregrine Asset Advisers's ATRS Position: Q4 2014 in Review

Peregrine Asset Advisers sold out of Antares Pharma, Inc. (ATRS) in Q4 2014, closing a stake of 53,034 shares — an estimated $97K sold.

Peregrine Asset Advisers first reported a position in ATRS in Q2 2013 and held it in 6 quarters. The position peaked at $237K in Q4 2013. 87 funds tracked by Wall St. Rank hold ATRS as of Q4 2014.

Peregrine Asset Advisers reported no remaining Antares Pharma, Inc. position as of Q4 2014 after selling out during the quarter.
Peregrine Asset Advisers sold 53,034 Antares Pharma, Inc. shares in Q4 2014, an estimated $97K.
Peregrine Asset Advisers first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 6 quarters.
Peregrine Asset Advisers's Antares Pharma, Inc. position peaked at $237K in Q4 2013.
87 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2014.

Based on Peregrine Asset Advisers's 13F filing for Q4 2014, filed 9 Feb 2015.